NCT06987942CompletedPhase 4
A Randomized, Controlled, Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (Split Virion) in Children Aged 7-12 Years
Sinovac (Dalian) Vaccine Technology Co., Ltd.1 site in 1 country899 target enrollmentStarted: September 21, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 899
- Locations
- 1
- Primary Endpoint
- GMT of VZV antibody
Study Overview
Brief Summary
The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and trivalent inactivated influenza vaccine (TIV hereafter). It will also evaluate the safety of simultaneous administration of the two vaccines. The main questions it aims to answer are:
- If geometric mean titer (GMT) of varicella zoster vrius (VZV) antibody in the simultaneous administration group is non-inferior to that in the varicella vaccine separate group.
- If GMT of hemagglutination inhibition (HI hereafter) antibody in the simultaneous administration group is non-inferior to that in the TIV separate group.
Participants in the simultaneous administration group received a single dose of varicella vaccine and TIV simultaneously on day 0. Participants in the separate groups received a single dose of varicella vaccine or TIV on day 0, respectively.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 7 Years to 12 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy children aged 7-12 years;
- •The subject or legal guardian can understand and sign the informed consent form (double signature is required for those over 8 years old);
- •Participants and their legal guardians voluntarily participate in the study and are able to comply with all study procedures;
- •Provide legal identity proof;
Exclusion Criteria
- •Vaccination history of varicella vaccine;
- •Had received a single dose of influenza vaccine for 2024-2025 season;
- •History of varicella;
- •History of severe allergic reactions to vaccines (such as acute anaphylaxis, angioedema, dyspnea, etc.);
- •Suffering from acute disease, severe chronic disease, acute exacerbation of chronic disease;
- •With any confirmed or suspected immunodeficiency disease, immunocompromised or receiving immunosuppressive therapy (including systemic steroid therapy);
- •With a history of congenital immune diseases or close contact with family members with a history of congenital immune diseases;
- •With encephalopathy, uncontrolled epilepsy, other progressive neurological disorders, history of Guillain-Barre syndrome;
- •Body temperature >37℃ at the time of vaccination;
- •Receipt of blood products within 3 months before receiving investigational vaccine;
- •Receipt of another study drug within 30 days before receipt of the investigational vaccine;
- •Receipt of live attenuated vaccine within 28 days before receipt of investigational vaccine;
- •Receipt of subunit or inactivated vaccine within 7 days before receipt of investigational vaccine;
- •Participated in other clinical trials before enrollment and were enrolled in another clinical trial during the follow-up period or planned to participate in another clinical trial within 3 months;
- •The participant had any other factors that were ineligible for vaccination by in the investigator's judgment.
Arms & Interventions
Simultaneous vaccination group
Experimental
Participants received a single dose of varicella vaccine and TIV on Day 0.
Intervention: Varicella vaccine+TIV (Biological)
Varicella vaccine separate group
Active Comparator
Participants received a single dose of varicella vaccine on Day 0.
Intervention: Varicella vaccine (Biological)
TIV separate group
Active Comparator
Participants received a single dose of TIV on Day 0.
Intervention: TIV (Biological)
Outcomes
Primary Outcomes
GMT of VZV antibody
Time Frame: Day 30 after the vaccination
GMT of VZV antibody on Day 30 after the vaccination.
GMT of HI antibody
Time Frame: Day 30 after vaccination
GMT of HI antibody on Day 30 after vaccination.
Secondary Outcomes
- Geometric mean increase (GMI) of VZV antibody(Day 30 after the vaccination)
- Seroconversion rate of VZV antibody(Day 30 after the vaccination)
- Seropositive rate of VZV antibody(Day 30 after the vaccination)
- GMI of HI antibody(Day 30 after the vaccination)
- Seroconversion rate of HI antibody(Day 30 after the vaccination)
- Seroprotection rate of HI antibody(Day 30 after the vaccination)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI VaccinesHand, Foot and Mouth DiseaseNCT03274102Sinovac Biotech Co., Ltd780
Completed
Phase 4
Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization VaccinesHand, Foot and Mouth DiseaseNCT04111432Sinovac Biotech Co., Ltd372
Active, not recruiting
Phase 2
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy AdolescentsMeningitis, MeningococcalNCT05087056GlaxoSmithKline312
Completed
Phase 3
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)Neisseria MeningitidisBacterial InfectionsVirus DiseasesNCT01553279MCM Vaccines B.V.284
Completed
Phase 3
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus VaccineHealthy VolunteersNCT03525119Takeda900